RxDoctor Payments Data

David Scoggin, MD

Family Medicine · Lancaster, OHNPI 1891766259

Payments from drug & device makers

$4,618in general payments, 2019–2025

Across 290 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$589
  • AbbVie$561
  • Pfizer$368
  • AstraZeneca$340
  • Otsuka America Pharmaceutical, Inc.$270
  • Astellas Pharma US Inc$202
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$4,611100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,618 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$70,279
Medicare patients
174
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$94,437
JanuviaSitagliptin Phosphate51$51,922
OzempicSemaglutide35$43,046
XareltoRivaroxaban40$41,073
JardianceEmpagliflozin39$34,806
MyrbetriqMirabegron25$26,328
Tresiba Flextouch U-200Insulin Degludec24$19,904
AbrysvoRsv Vacc, Pref A And Pref B/Pf59$18,494
TrulicityDulaglutide11$10,127
Tresiba Flextouch U-100Insulin Degludec17$8,605
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$8,203
Spiriva RespimatTiotropium Bromide13$7,522
Atorvastatin Calcium510$7,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,892
Duloxetine Hcl102$4,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Premarin$368$115,221178 claims
MerckJanuvia$98$51,92251 claims
Novo NordiskOzempic$589$43,04635 claims
Boehringer IngelheimJardiance, Spiriva Respimat$44$42,32852 claims
Johnson & JohnsonXarelto$14$41,07340 claims
Astellas Pharma US IncMyrbetriq$202$26,32825 claims
GSKTrelegy Ellipta, Shingrix$42$11,71033 claims
Lilly USA, LLCTrulicity$151$10,12711 claims
AbbVieSynthroid$561$1,37643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →